Petosemtamab
- Product Name
- Petosemtamab
- CAS No.
- 2213450-26-9
- Chemical Name
- Petosemtamab
- Synonyms
- MCLA 158;Petosemtamab;Research Grade Petosemtamab;Research Grade Petosemtamab (DHB86918)
- CBNumber
- CB98081185
- Formula Weight
- 0
- MOL File
- Mol file
Petosemtamab Property
- form
- Liquid
- color
- Colorless to light yellow
Petosemtamab Chemical Properties,Usage,Production
Uses
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2].
in vivo
MCLA-158 (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2].
| Animal Model: | Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2] |
| Dosage: | 25 mg/kg/week |
| Administration: | Intravenous injection (i.v.) for 6 weeks. |
| Result: | Inhibited tumor growth. |
IC 50
EGFR: 0.22 nM (Kd); LGR5: 0.85 nM (Kd)
References
[1] Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.
[2] Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl
Petosemtamab Preparation Products And Raw materials
Raw materials
Preparation Products
Petosemtamab Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58